HOME Press Releases Biomarker Technologies Market worth 74.51 Billion USD by 2022



Biomarker Technologies Market worth 74.51 Billion USD by 2022


The report "Biomarker Technologies Market by Profiling Technology (Chromatography, NGS, PCR, Mass Spectrometry, Immunoassay, Liquid Biopsy (ddPCR, DHPLC)), Research Area (Proteomics, Lipidomics), Application (Biomarker Validation, Biomarker Discovery) - Global Forecast to 2022", The global biomarker technologies market is expected to reach USD 74.51 Billion in 2022 from USD 46.97 Billion in 2017, at a rate (CAGR) of 9.7% during the forecast period. The growth of this market is supported by increasing healthcare expenditure, rising availability of R&D funding and pace of research, and the utility of biomarkers in diagnosis.

     Download PDF Brochure     Speak to Analyst     Inquiry Before Buying

Browse 134 market data Tables and 7 Figures spread through 122 Pages and in-depth TOC on "Biomarker Technologies Market by Profiling Technology (Chromatography, NGS, PCR, Mass Spectrometry, Immunoassay, Liquid Biopsy (ddPCR, DHPLC)), Research Area (Proteomics, Lipidomics), Application (Biomarker Validation, Biomarker Discovery) - Global Forecast to 2022"
https://www.marketsandmarkets.com/Market-Reports/biomarker-technologies-market-190358765.html
Early buyers will receive 10% customization on reports.

The consumables segment accounted for the largest share of the global biomarker technologies market in 2017

By product type, the biomarker technologies market is classified into consumables, instruments, services, and software/informatics. In 2017, the consumables segment was expected to account for the largest share of the market due to their larger sales volume as compared to instruments. The consumables market is further segmented into reagents & kits and chromatography columns. The reagent & kits segment accounted for the largest share of the consumables market in 2017.

The clinical diagnostics segment is expected to grow at the highest CAGR in the biomarker technologies market for liquid biopsy during the forecast period.

By application, the biomarker technologies market for liquid biopsy is divided into clinical diagnostics, research, and drug discovery and development. The clinical diagnostics application segment is expected to grow at the highest CAGR during the forecast period. This positive growth is due to the advantages of liquid biopsy, such as its minimally invasive nature and time & cost savings incurred during use.

The mass spectrometry segment is projected to grow at the highest CAGR.

By type of profiling technology, the biomarker technologies market is divided into immunoassay, PCR, imaging technology, mass spectrometry, NGS, chromatography, cytogenetics, and other technologies. MS is projected to grow at the highest CAGR during the forecast period. It provides rapid and sensitive qualitative and quantitative analysis of biomolecules (proteins, peptides, oligosaccharides, lipids, DNA, and RNA), drugs, and metabolites. Apart from research applications, currently, the clinical applications of MS continue to expand.

Asia Pacific is expected to grow at the highest CAGR in the biomarker technologies market during the forecast period.

The high growth of the Asia Pacific market is attributed to the rising incidence of cancer, growth in geriatric population, and support from private and public organizations for biomarker research.

Market Players

The key players in the biomarker technologies market are Thermo Fisher Scientific (US), Agilent Technologies (US), Roche (Switzerland), Danaher Corporation (US), Waters Corporation (US), Shimadzu Corporation (Japan), and Bio-Rad Laboratories (US).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

We will organize an analyst call and demonstrate the latent opportunities and threats which will likely impact your business, at no cost.

Speak to Analyst


* Name :
* Business Email :
* Phone :
* Designation :
* Country:
Report MD 6249: Biomarker Technologies Market by Profiling Technology (Chromatography, NGS, PCR, Mass Spectrometry, Immunoassay, Liquid Biopsy (ddPCR, DHPLC)), Research Area (Proteomics, Lipidomics), Application (Biomarker Validation, Biomarker Discovery) - Global Forecast to 2022
* Enter the text from the image
   to the textbox :
3 4 3 9 5  
Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports